Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its immunology and rare-disease treatment portfolio in one of the company's largest-ever acquisitions. The deal materially broadens Biogen's pipeline in complement-mediated and rare-disease indications and is likely to be viewed positively for Biogen's growth prospects and strategic positioning in specialty biotech. Expect the transaction to be sector-moving and to influence M&A comparable valuations in the biotech space.

Analysis

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its immunology and rare-disease treatment portfolio in one of the company's largest-ever acquisitions. The deal materially broadens Biogen's pipeline in complement-mediated and rare-disease indications and is likely to be viewed positively for Biogen's growth prospects and strategic positioning in specialty biotech. Expect the transaction to be sector-moving and to influence M&A comparable valuations in the biotech space.